Prolyl endopeptidase and dipeptidyl peptidase IV are distantly related members of the same family of serine proteasesPOLGAR, L; SZABO, E.Biological chemistry Hoppe-Seyler. 1992, Vol 373, Num 7, pp 361-366, issn 0177-3593Conference Paper

Reaction of dipeptidylpeptidase IV with substrate-analogous azapeptidesNEUMANN, U; STEINMETZER, T; BARTH, A et al.Journal of enzyme inhibition. 1991, Vol 4, Num 3, pp 213-226, issn 8755-5093Article

Novel series of 3-amino-N-(4-aryl-1,1-dioxothian-4-yl)butanamides as potent and selective dipeptidyl peptidase IV inhibitorsNITTA, Aiko; FUJII, Hideaki; SAKAMI, Satoshi et al.Bioorganic & medicinal chemistry letters (Print). 2012, Vol 22, Num 23, pp 7036-7040, issn 0960-894X, 5 p.Article

Serum activity of dipeptidyl peptidase IV (DPPIV; EC 3.4.14.5) in breast-fed infants with symptoms of allergyJARMOŁOWSKA, Beata; BIELIKOWICZ, Krzysztof; IWAN, Małgorzata et al.Peptides (New York, NY. 1980). 2007, Vol 28, Num 3, pp 678-682, issn 0196-9781, 5 p.Article

Hyperglycaemia increases dipeptidyl peptidase IV activity in diabetes mellitusMANNUCCI, E; PALA, L; CIANI, S et al.Diabetologia (Berlin). 2005, Vol 48, Num 6, pp 1168-1172, issn 0012-186X, 5 p.Article

The dipeptidyl peptidase IV (CD26, EC 3.4.14.5) inhibitor vildagliptin is a potent antihyperalgesic in rats by promoting endomorphin-2 generation in the spinal cordKIRALY, Kornél; LAMBEIR, Anne-Marie; SZALAI, Judit et al.European journal of pharmacology. 2011, Vol 650, Num 1, pp 195-199, issn 0014-2999, 5 p.Article

Physiological and Pharmacological Mechanisms through which the DPP-4 Inhibitor Sitagliptin Regulates Glycemia in MiceWAGET, Aurélie; CABOU, Cendrine; SULPICE, Thierry et al.Endocrinology (Philadelphia). 2011, Vol 152, Num 8, pp 3018-3029, issn 0013-7227, 12 p.Article

Clinical Pharmacokinetics and Pharmacodynamics of VildagliptinHE, Yan-Ling.Clinical pharmacokinetics. 2012, Vol 51, Num 3, pp 147-162, issn 0312-5963, 16 p.Article

Effects of sitagliptin in diabetic patients with nonalcoholic steatohepatitisYILMAZ, Yusuf; YONAL, Oya; DEYNELI, Oguzhan et al.Acta gastro-enterologica belgica (English ed.). 2012, Vol 75, Num 2, pp 240-244, issn 1784-3227, 5 p.Article

Effects of the dipeptidyl peptidase-IV inhibitor ASP8497 on glucose tolerance in animal models of secondary failureSOMEYA, Yuka; NAKANO, Ryosuke; UCHIYAMA, Yasuo et al.European journal of pharmacology. 2009, Vol 622, Num 1-3, pp 71-77, issn 0014-2999, 7 p.Article

ASP8497 is a novel selective and competitive dipeptidyl peptidase-IV inhibitor with antihyperglycemic activityMATSUYAMA-YOKONO, Akiko; TAHARA, Atsuo; NAKANO, Ryosuke et al.Biochemical pharmacology. 2008, Vol 76, Num 1, pp 98-107, issn 0006-2952, 10 p.Article

Inhibiteurs des DPP-4 et maladies cardiovasculaires: Les études EXAMINE et SAVORYOMTOV, Bernard.Diabète & obésité. 2013, Vol 8, Num 73, pp 299-300, issn 1957-5238, 2 p.Conference Paper

Effects of antidiabetic drugs on dipeptidyl peptidase IV activity : Nateglinide is an inhibitor of DPP IV and augments the antidiabetic activity of glucagon-like peptide-1DUFFY, Nicola A; GREEN, Brian D; IRWIN, Nigel et al.European journal of pharmacology. 2007, Vol 568, Num 1-3, pp 278-286, issn 0014-2999, 9 p.Article

saxagliptine ^(ONGLYZA°) seule ou associée: Pas moins de complications, peut-être plus d'insuffisances cardiaquesLa Revue Prescrire. 2014, Vol 34, Num 366, issn 0247-7750, p. 256Article

Pharmacokinetic—Pharmacodynamic Modelling of Biomarker Response to Sitagliptin in Healthy VolunteersKIM, Bo-Hyung; SUNG EUN KIM; DONGWOO KANG et al.Basic & clinical pharmacology & toxicology (Print). 2013, Vol 113, Num 2, pp 113-125, issn 1742-7835, 13 p.Article

Non-Alcoholic Fatty Liver Disease Adversely Affects the Glycemic Control Afforded by SitagliptinIWASAK, Tomoyuki; TOMENO, Wataru; YONEDA, Masato et al.Hepato-gastroenterology. 2012, Vol 59, Num 117, pp 1522-1525, issn 0172-6390, 4 p.Article

Recent Advances in Non-Peptidomimetic Dipeptidyl Peptidase 4 Inhibitors: Medicinal Chemistry and Preclinical AspectsLIU, Y; HU, Y; LIU, T et al.Current medicinal chemistry. 2012, Vol 19, Num 23, pp 3982-3999, issn 0929-8673, 18 p.Article

Sitagliptin Exerts an Antinflammatory ActionMAKDISSI, Antoine; GHANIM, Husam; VORA, Mehul et al.The Journal of clinical endocrinology and metabolism. 2012, Vol 97, Num 9, pp 3333-3341, issn 0021-972X, 9 p.Article

EFFECT OF THE DIPEPTIDYL PEPTIDASE-4 INHIBITOR SITAGLIPTIN IN OLDER ADULTS WITH TYPE 2 DIABETES MELLITUSSTAFFORD, Sara; ELAHI, Dariush; MENEILLY, Graydon S et al.Journal of the American Geriatrics Society. 2011, Vol 59, Num 6, pp 1148-1149, issn 0002-8614, 2 p.Article

Disposition of Vildagliptin, a Novel Dipeptidyl Peptidase 4 Inhibitor, in Rats and DogsHANDAN HE; TRAN, Phi; HEQUN YIN et al.Drug metabolism and disposition. 2009, Vol 37, Num 3, pp 545-554, issn 0090-9556, 10 p.Article

Dipeptidyl Peptidase-4 Inhibition: Linking Chemical Properties to Clinical SafetyMATTEUCCI, E; GIAMPIETRO, O.Current medicinal chemistry. 2011, Vol 18, Num 31, pp 4753-4760, issn 0929-8673, 8 p.Article

Saxagliptin: A New Dipeptidyl Peptidase 4 Inhibitor for Type 2 DiabetesBORJA-HART, Nancy L; WHALEN, Karen L.The Annals of pharmacotherapy. 2010, Vol 44, Num 6, pp 1046-1053, issn 1060-0280, 8 p.Article

Absorption, Metabolism, and Excretion of [¹⁴C]Vildagliptin, a Novel Dipeptidyl Peptidase 4 Inhibitor, in HumansHANDAN HE; TRAN, Phi; HOWARD, Dan et al.Drug metabolism and disposition. 2009, Vol 37, Num 3, pp 536-544, issn 0090-9556, 9 p.Article

Sitagliptin, an dipeptidyl peptidase-4 inhibitor, does not alter the pharmacokinelics of the sulphonylurea, glyburide, in healthy subjectsMISTRY, Goutam C; BERGMAN, Arthur J; WEI ZHENG et al.British journal of clinical pharmacology. 2008, Vol 66, Num 1, pp 36-42, issn 0306-5251, 7 p.Article

Sitagliptine : allergies graves = Sitagliptin and severes allergiesLa Revue Prescrire. 2008, Vol 28, Num 302, pp 907-907, issn 0247-7750, 1 p.Article